Molbio swings to US$7.16M Q1 profit after US$127.7M IPO
What's the deal? Molbio Diagnostics posted a profit of US$7.16M in the June quarter, reversing a US$3.25M loss a year earlier. Total income rose to US$55.9M, up from US$13.6M in Q1 FY26.
What drove it? Sales of the company's Truenat test-kits jumped, with volumes reaching 62.4 lakh units against 790,000 units a year earlier. Truenat is designed to detect a range of infectious diseases at the point of care.
Why now? The results are Molbio's first as a listed company. It raised about US$127.7M through an initial public offering and was listed on the bourses on August 17.
What they're saying: "FY27 is a milestone year for Molbio, marking our transition to a listed company," said Sriram Natarajan, executive director and chief executive officer. He added that the firm has "begun the year on a strong note, with healthy growth across both revenue and profitability in Q1."
The signal: The sharp swing from loss to profit, backed by an eightfold jump in test-kit volumes, signals early momentum for the newly-listed diagnostics firm as it builds on point-of-care testing demand.
Read more: money.rediff.com
Image credit: US Army Africa
